A Rare but Important Pregnancy Condition
Intrahepatic Cholestasis of Pregnancy (ICP) is a liver condition unique to pregnancy. It disrupts normal bile flow from the liver, causing bile acids to spill into the bloodstream. While uncommon, this condition can pose significant risks to the unborn baby.
Although I do not treat ICP directly, I believe in equipping my patients with knowledge. At our Montgomery County endocrine and metabolic clinic, we emphasize full-body awareness. Understanding ICP helps women advocate for better care during pregnancy—especially when symptoms overlap with hormonal or metabolic shifts.
Summary Table: ICP at a Glance
| Feature | Details |
|---|---|
| Condition | Intrahepatic Cholestasis of Pregnancy |
| When it Occurs | Mostly in the 3rd trimester, can appear earlier |
| Main Symptom | Intense itching, especially on palms and soles at night |
| Cause | Impaired bile flow in the liver due to hormonal and genetic factors |
| Common Labs | Elevated bile acids, abnormal liver enzymes (ALT, AST) |
| Risks | Fetal distress, preterm labor, stillbirth |
| Treatment | Ursodeoxycholic acid, fetal surveillance, early delivery |
| Follow-Up | Symptoms resolve postpartum; monitor liver function |
| Seen by | OB-GYNs, maternal-fetal medicine, sometimes hepatologists |
What Causes ICP?
ICP results from impaired bile movement through the liver during pregnancy. Bile acids accumulate in the bloodstream, irritating the skin and placing the fetus at risk.
Several factors may increase risk:
- Hormonal shifts, particularly high estrogen and progesterone levels
- Genetic susceptibility (more common in certain populations)
- Twin or multiple pregnancies
- Personal or family history of liver conditions
- Underlying metabolic or thyroid imbalances may worsen the symptom burden
While hormones trigger the dysfunction, the liver’s inability to clear bile effectively becomes the core issue.
Recognizing the Signs
The hallmark symptom is intense itching without a rash. It usually affects the hands and feet, intensifying at night and disrupting sleep.
Other signs may include:
- Dark-colored urine
- Light-colored or greasy stools
- Fatigue or low energy
- Discomfort in the upper right abdomen
- Yellowing of the skin or eyes (jaundice) in more advanced cases
The itching often starts before lab tests show any changes. If you’re pregnant and notice sudden nighttime itching, bring it up with your OB-GYN right away—even if your labs are still normal.
Why It Matters for Baby’s Health
For mothers, ICP usually resolves after delivery. For babies, however, the stakes are higher. Elevated bile acids increase the risk of:
- Preterm delivery
- Meconium-stained amniotic fluid
- Fetal distress
- Stillbirth, especially beyond 37 weeks without intervention
Most OB-GYNs recommend increased monitoring and sometimes early delivery once bile acids surpass 40-100 μmol/L or symptoms escalate. This proactive approach helps minimize fetal risk while allowing time for lung maturity.
How Is It Diagnosed?
Diagnosis relies on clinical judgment supported by key blood tests:
- Serum bile acids: Gold standard; levels above 10–14 μmol/L raise concern
- Liver enzymes: ALT and AST often elevated
- Other labs: Total bilirubin, GGT, and hepatitis panel to rule out alternate causes
In cases of diagnostic uncertainty, repeat bile acid testing may be needed, especially if symptoms persist but initial labs are normal.
What Else Could It Be?
Pregnancy can bring on many symptoms that resemble ICP. A thorough evaluation helps rule out:
- HELLP syndrome (Hemolysis, Elevated Liver enzymes, Low Platelets)
- Acute fatty liver of pregnancy
- Preeclampsia-related liver dysfunction
- Viral hepatitis or gallbladder disease
These conditions differ in timing, severity, and lab patterns. That’s why a multidisciplinary approach often includes OB-GYNs, hepatologists, and occasionally endocrinologists—especially if thyroid or metabolic labs are also abnormal.
How Is It Treated?
Once diagnosed, ICP is actively managed to reduce fetal risk. Strategies include:
- Ursodeoxycholic acid (ursodiol) to lower bile acid levels and relieve itching
- Antihistamines or topical agents to reduce nighttime discomfort
- Fetal non-stress tests and biophysical profiles multiple times weekly
- Early delivery between 36–39 weeks, depending on bile acid levels and symptom severity
After delivery, symptoms and labs usually normalize within days. Still, liver function is rechecked postpartum to confirm resolution.
What About the Next Pregnancy?
Women with prior ICP face a higher risk of recurrence in future pregnancies—estimated at 60–90%. Some providers consider starting ursodiol earlier in subsequent pregnancies as a preventive measure.
Also, women who experienced ICP should inform all future providers, including endocrinologists and lipid specialists, given the metabolic-liver interface.
Why Holistic, Individualized Care Matters
Even though we don’t treat ICP at our practice, we never ignore its signs. Our role includes recognizing when liver or skin symptoms might mimic thyroid, adrenal, or nutritional conditions—especially during pregnancy.
For example:
- Thyroid dysfunction can elevate liver enzymes
- Vitamin B12 or folate deficiency may cause fatigue
- Omega-3 deficiency can worsen skin irritation
By viewing each patient through multiple lenses—thyroid, metabolic, nutritional—we help uncover what’s relevant and when to refer.
Our care model doesn’t stop at the diagnosis. It asks: what else might be happening, and who needs to be looped in?
Final Takeaway
Intrahepatic Cholestasis of Pregnancy is rare but urgent. Intense itching in pregnancy should never be dismissed. Early diagnosis and collaboration with your obstetrician or maternal-fetal medicine specialist can make all the difference.
At our practice, we remain alert to the interconnected health changes that occur during pregnancy—even those beyond our direct treatment scope. If you have questions about symptoms that could relate to hormone, thyroid, or metabolic issues during pregnancy, we’re here to guide you with thoughtful, whole-body care.
- Reproductive Health and Liver Disease: Practice Guidance by the American Association for the Study of Liver Diseases. Sarkar M, Brady CW, Fleckenstein J, et al. Hepatology (Baltimore, Md.). 2021;73(1):318-365. doi:10.1002/hep.31559.
- Society for Maternal-Fetal Medicine Consult Series #53: Intrahepatic Cholestasis of Pregnancy: Replaces Consult #13, April 2011. Lee RH, Mara Greenberg, Metz TD, Pettker CM. American Journal of Obstetrics and Gynecology. 2021;224(2):B2-B9. doi:10.1016/j.ajog.2020.11.002.
- Intrahepatic Cholestasis of Pregnancy: Natural History and Current Management. Roediger R, Fleckenstein J. Seminars in Liver Disease. 2021;41(1):103-108. doi:10.1055/s-0040-1722264.
- Intrahepatic Cholestasis in Pregnancy: Review of the Literature. Piechota J, Jelski W. Journal of Clinical Medicine. 2020;9(5):E1361. doi:10.3390/jcm9051361.
- ACG Clinical Guideline: Liver Disease and Pregnancy. Tran TT, Ahn J, Reau NS. The American Journal of Gastroenterology. 2016;111(2):176-94; quiz 196. doi:10.1038/ajg.2015.430.
- Review of a Challenging Clinical Issue: Intrahepatic Cholestasis of Pregnancy. Ozkan S, Ceylan Y, Ozkan OV, Yildirim S. World Journal of Gastroenterology. 2015;21(23):7134-41. doi:10.3748/wjg.v21.i23.7134.
About Dr. Gerti Tashko, MD
Dr. Gerti Tashko, MD, is a board-certified endocrinologist based in Montgomery County, Maryland. He is uniquely certified in endocrinology, lipidology, hypertension, and obesity medicine. His practice offers comprehensive, root-cause-focused metabolic and endocrine care, available both virtually and in person. He uses advanced diagnostics, personalized nutrition, and preventive medicine to optimize long-term health outcomes.



